Event

Pulmonary toxicity from checkpoint inhibitors such as anti-programmed death-1 (PD-1) therapies is an emerging entity with high morbidity and mortality. In this session, we will review the pathobiology of PD-1 toxicity, and discuss diagnostic and treatment considerations in patients with suspected PD-1 pneumonitis.